Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation
Name
nihms811153.pdf
Size
2.48 MB
Format
Adobe PDF
Checksum (MD5)
7a45bcce9a56d57096cad1c04b46eb8b
Author(s)
Jenney, Anne P
Swantek, Jennifer L
Burke, John M
Sorger, Peter K
Jones II, Douglas S.
Lauffenburger, Douglas A
Date Issued
October 2016
Journal
Nature Chemical Biology
Publisher
Springer Nature
Citation
Jones, Douglas S., et al. “Profiling Drugs for Rheumatoid Arthritis That Inhibit Synovial Fibroblast Activation.” Nature Chemical Biology, vol. 13, no. 1, Jan. 2017, pp. 38–45.
Version
Author's final manuscript
Abstract
Activation of synovial fibroblasts (SFs) contributes to rheumatoid arthritis (RA) by damaging synovial membranes and generating inflammatory cytokines that recruit immune cells to the joint. In this paper we profile cytokine secretion by primary human SFs from healthy tissues and from donors with RA and show that SF activation by TNF, IL-1α, and polyinosinic-polycytidylic acid (Poly(I:C)) cause secretion of multiple cytokines found at high levels in RA synovial fluids. We used interaction multiple linear regression to quantify therapeutic and countertherapeutic drug effects across activators and donors and found that the ability of drugs to block SF activation was strongly dependent on the identity of the activating cytokine. (5z)-7-oxozeaenol (5ZO), a preclinical drug that targets transforming growth factor-β-activated kinase 1 (TAK1), was more effective at blocking SF activation across all contexts than the approved drug tofacitinib, which supports the development of molecules similar to 5ZO for use as RA therapeutics.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/NCHEMBIO.2211
